Avacopan is a safe, non-inferior alternative to high-dose prednisone for treating GPA and MPA. It allows for a significant reduction in steroid use while maintaining disease remission. Discuss your specific steroid-related side effect profile with your rheumatologist to see if this treatment is right for your long-term management plan.
A 2026 re-adjudication of the ADVOCATE trial confirms avacopan is a non-inferior, steroid-sparing treatment for ANCA-associated vasculitis.